• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Tuesday, April 13, 2021
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

MUSC is first in nation to enroll kids in trial of novel MIS-C therapy

Bioengineer by Bioengineer
March 10, 2021
in Science News
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Using an investigational cell therapy, Medical University of South Carolina pediatricians successfully treated two patients with multisystem inflammatory syndrome in children, a rare but life-threatening complication of COVID-19.

IMAGE

Credit: Medical University of South Carolina, Sarah Pack

A team of pediatricians at the Medical University of South Carolina (MUSC) was the first in the nation to enroll patients with multisystem inflammatory syndrome in children (MIS-C), a rare but life-threatening complication of COVID-19, in a trial of remestemcel-L. This investigational cell therapy, developed and manufactured by Mesoblast, New York, New York, had previously been shown safe and effective for other inflammatory conditions. The MUSC team reports in Pediatrics that the two children enrolled thus far showed significant improvement within 24 hours of remestemcel-L administration.

“While it appears to many people that COVID is no big deal in children, this potential complication, although rare, is very, very serious,” said MUSC Children’s Health pediatric infectious disease physician, Allison Eckard, M.D., who is leading the local trial. “In South Carolina, we have had over 70 cases of MIS-C and one death. That is way more than we’d like to see in children.”

Too often, MIS-C is not recognized until children are already critically ill.

“The tricky part about MIS-C is that, in many cases, the families don’t know that the children ever had COVID because, in general, children have very mild symptoms,” said Eckard.

MIS-C can also be missed because its symptoms are vague, and so it can easily be mistaken for other illnesses.

Although the cause of MIS-C is unknown, Eckard speculates that the body’s reaction to COVID-19 likely sets off a cascade of unchecked inflammation.

“Although inflammation has a role to play in the body, excessive inflammation is bad and causes organ damage, organ failure and a lot of other complications,” she said.

The current standard of care for MIS-C is nonspecific. It consists of using steroids or antibodies derived from donated plasma to turn down all aspects of the immune system.

“The novel treatment we are using is a little bit more specific,” said Eckard.

Remestemcel-L is a cellular therapy derived from a special type of cell that forms in bone marrow.

“These bone marrow cells, donated by healthy adults, are known to turn down inflammation,” said Eckard. They are able to target the specific parts of the immune system that are most relevant to MIS-C.

The cells are also able to improve the inner lining of the blood vessel, targeting the most serious and potentially long-term effects of MIS-C: cardiac and cardiovascular involvement. Remestemcel-L improves blood pressure and the flow of blood to where it needs to be.

“We rely on the heart to pump blood adequately to all the other organs,” said Eckard. “The same applies to blood vessels and the cardiovascular system. When they don’t work properly, your body can’t pump blood effectively to vital organs.”

Nationwide studies have already been conducted on the use of remestemcel-L to treat graft-vs-host disease in children, a condition that can develop after receiving a bone marrow transplant, and MUSC participated in some of them. Other studies have also assessed its usefulness for treating cardiac complications in adults. However, MUSC is the only institution thus far to use remestemcel-L for the purpose of MIS-C.

“We always worry in pediatrics about the safety of new therapies. But because of our experience here at MUSC with hundreds of children enrolled in a remestemcel-L trial for graft-vs. host disease, we felt really good about its safety profile,” said Eckard.

Thus far, two children have been enrolled in the trial and treated with remestemcel-L. They were chosen because they still had underlying inflammation and cardiac dysfunction despite having received standard-of-care therapy. Eckard hopes that the investigational therapy will help to protect these children from long-term cardiovascular complications.

“People are always very hesitant to try new things if they think the current therapy is working. But what I say to that is we do not know the long-term effects of MIS-C,” said Eckard.

Although it is too early to know if the novel therapy will protect against long-term complications, Eckard is heartened by the therapy’s short-term effects, which were reported in the Pediatrics article.

“There were some dramatic improvements within 24 hours of giving the treatment in both of the children, and that is what compelled us to publish those two cases,” said Eckard.

The remestemcel-L trial for use in MIS-C aims to enroll 50 children with cardiac dysfunction nationwide. If the investigational treatment proves effective at treating MIS-C, it might also be studied in children with other inflammatory syndromes.

Future studies will aim to determine if the administration of remestemcel-L is alone responsible for the improvement of patients or if it still needs to be administered with plasma antibodies, which is the current but more expensive standard of care. The current standard-of-care therapies also have unwanted side effects that might be avoided if remestemcel-L is used instead.

“We want people to be more aware of the condition, but we also want to show people that we’ve had success with this therapy, in terms of safety and effectiveness, and encourage others to consider using it at their own institutions,” said Eckard.

###

Disclosure: One of the article’s authors is a consultant to Mesoblast and another is an employee. None of the other authors has conflicts of interest to disclose.

About MUSC

Founded in 1824 in Charleston, MUSC is the oldest medical school in the South as well as the state’s only integrated academic health sciences center with a unique charge to serve the state through education, research and patient care. Each year, MUSC educates and trains more than 3,000 students and nearly 800 residents in six colleges: Dental Medicine, Graduate Studies, Health Professions, Medicine, Nursing and Pharmacy. The state’s leader in obtaining biomedical research funds, in fiscal year 2019, MUSC set a new high, bringing in more than $284 million. For information on academic programs, visit musc.edu.

As the clinical health system of the Medical University of South Carolina, MUSC Health is dedicated to delivering the highest quality patient care available while training generations of competent, compassionate health care providers to serve the people of South Carolina and beyond. Comprising some 1,600 beds, more than 100 outreach sites, the MUSC College of Medicine, the physicians’ practice plan and nearly 325 telehealth locations, MUSC Health owns and operates eight hospitals situated in Charleston, Chester, Florence, Lancaster and Marion counties. In 2020, for the sixth consecutive year, U.S. News & World Report named MUSC Health the No. 1 hospital in South Carolina. To learn more about clinical patient services, visit muschealth.org.

MUSC and its affiliates have collective annual budgets of $3.2 billion. The more than 17,000 MUSC team members include world-class faculty, physicians, specialty providers and scientists who deliver groundbreaking education, research, technology and patient care.

Media Contact
Heather Woolwine
[email protected]

Original Source

https://web.musc.edu/about/news-center/2021/03/10/novel-misc-therapy

Related Journal Article

http://dx.doi.org/10.1542/peds.2020-046573

Tags: BiotechnologyCardiologyClinical TrialsCritical Care/Emergency MedicineHealth CareImmunology/Allergies/AsthmaInfectious/Emerging DiseasesMedicine/HealthPediatricsPublic Health
Share12Tweet7Share2ShareShareShare1

Related Posts

IMAGE

Research suggests SEC’s increasing focus on terrorism may limit financial oversight

April 12, 2021
IMAGE

Plastic planet: Tracking pervasive microplastics across the globe

April 12, 2021

Scientists watch 2D puddles of electrons emerge in a 3D superconducting material

April 12, 2021

Leader in global nitrogen cycle research Eric Davidson named Jefferson Science Fellow

April 12, 2021

Leave a Reply Cancel reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

POPULAR NEWS

  • IMAGE

    Terahertz accelerates beyond 5G towards 6G

    852 shares
    Share 341 Tweet 213
  • Jonathan Wall receives $1.79 million to develop new amyloidosis treatment

    60 shares
    Share 24 Tweet 15
  • UofL, Medtronic to develop epidural stimulation algorithms for spinal cord injury

    56 shares
    Share 22 Tweet 14
  • A sturdier spike protein explains the faster spread of coronavirus variants

    43 shares
    Share 17 Tweet 11

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

Medicine/HealthEcology/EnvironmentInfectious/Emerging DiseasesBiologyCell BiologycancerTechnology/Engineering/Computer ScienceMaterialsChemistry/Physics/Materials SciencesGeneticsClimate ChangePublic Health

Recent Posts

  • Research suggests SEC’s increasing focus on terrorism may limit financial oversight
  • Plastic planet: Tracking pervasive microplastics across the globe
  • Scientists watch 2D puddles of electrons emerge in a 3D superconducting material
  • Leader in global nitrogen cycle research Eric Davidson named Jefferson Science Fellow
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In